{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031575","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.823322+00:00","generated_at":"2026-06-21T21:29:10.180766+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cingulate Q3 net loss $4.0M; cash $9.8M, funds only through Q1 2023; Phase 3 ADHD trial starts Dec 2022","bullets":["Q3 2022 net loss $4.0M vs $15.3M in Q3 2021; cash and equivalents $9.8M, expected to fund only through first quarter 2023.","Phase 3 adult dose-optimization study for lead ADHD candidate CTx-1301 to commence December 2022; NDA submission targeted H1 2024.","Executed Master Services Agreement with Societal CDMO to manufacture clinical, registration, and commercial batches of CTx-1301.","Anxiety candidate CTx-2103 triple-release buspirone achieved solubility targets; clinical program design underway.","Phase 1/2 bioavailability study for ADHD candidate CTx-1302 (dextroamphetamine) planned for first half 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031575","json":"https://secwatch.observer/filing/0001493152-22-031575.json","markdown":"https://secwatch.observer/filing/0001493152-22-031575.md","text":"https://secwatch.observer/filing/0001493152-22-031575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/0001493152-22-031575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:29:10.180766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95387275a02780981f55e2aeb8542545527bb70f","claim":"Cingulate Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Cingulate Inc. (the “Company”) issued a press release announcing its financial results for the third quarter of 2022 and providing a clinical and business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315222031575/0001493152-22-031575-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}